Lannett Co Inc (LCI) News
Filter LCI News Items
LCI News Results
|Loading, please wait...|
LCI News Highlights
- 500 - Internal server error
- 500 - Internal server error
Latest LCI News From Around the Web
Below are the latest news stories about Lannett Co Inc that investors may wish to consider to help them evaluate LCI as an investment opportunity.
Lannett LCI shares rallied 10.1% within the final buying and selling session to shut at $5.33. This transfer may be attributable to notable quantity with the next variety of shares being traded than in a typical session. This compares to the inventorys 14.2% achieve over the previous 4 weeks. Earlier this month, Lannett introduced that  The post Lannett (LCI) Soars 10.1%: Is Additional Upside Left within the Inventory? appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Akebia, Biontech, Celltrion Healthcare, Eli Lilly, Iaso, Innovent Biologics, Johnson & Johnson, Lannett Co., Micurx, Moderna, Neuren, Neurorx, Otsuka, Pfizer, Regeneron, Respirent, Visen.
Raymond James analyst Elliot Wilbur initiated coverage with a Hold rating on Lannett (LCI) today. The companys shares closed last Tuesday at $4. The post Raymond James Initiates a Hold Rating on Lannett (LCI) appeared first on Smarter Analyst .
Lannett Company, Inc. (NYSE: LCI) today announced the U.S. Food and Drug Administration (FDA) has accepted the Abbreviated New Drug Application (ANDA) for Fluticasone Propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg), which was submitted by Lannett on behalf of its strategic alliance partner, Respirent Pharmaceuticals Co. Ltd. The FDA assigned a Generic Drug User Fee Act of 2017 (GDUFA II) goal date for this priority original ANDA of January 31, 2022.
On Friday, investors were refusing the pill that is generic-drug specialist Lannett (NYSE: LCI). The company's shares took a painful hit, sinking by 13% after the company got the toss from a high-profile stock index. After market close Thursday S&P Dow Jones Indices, the company responsible for the closely followed S&P suite of securities indexes, announced a set of adjustments to three of its stock indicators.
Organon Set to Join S&P 500; HollyFrontier to Join S&P MidCap 400; Service Properties Trust to Join S&P SmallCap 600
Organon & Co. (NYSE: OGN) will be added to the S&P 500 prior to the open of trading on Thursday, June 3, replacing HollyFrontier, which will be removed from the S&P 500 effective prior to the open of trading on Friday, June 4.
Lannett (LCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lannett To Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call On Wednesday, May 5
Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 third quarter on Wednesday, May 5, 2021, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.
Lannett Company, Inc. (NYSE: LCI) (the "Company" or "Lannett") today announced the pricing of the $350 million aggregate principal amount of 7.75% senior secured notes due 2026 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act") and outside the United States to persons other than U.S. persons in reliance upon Regulation S under the Securities Act. The sale of the Notes to the initial purchasers is expected to settle on April 22, 2021, subject to customary closing conditions.